ISAE-SUPAERO
19.11.2020 13:17:05 CET | Business Wire | Press release
A space dedicated to knowledge sharing and entrepreneurship located at the heart of ISAE-SUPAERO, the InnovSpace encourages collaborative innovative projects. The 8600 sq ft building will house a prototyping area, a Digital Lab as well as a start up space.
A space dedicated to creativity and innovation
InnovSpace aims at offering a framework for innovative projects with a mix of physical space, a community of users and entertainment. ISAE-SUPAERO students, alumni and researchers can all benefit from the InnovSpace but it will also be accessible for students and researchers from other universities and businesses wishing to collaborate on projects with ISAE-SUPAERO students.
“Our vision is to create a real community. Innovation is not a personal matter but requires to be open and to exchange ideas. This is why leading businesses are creating these kind of spaces to break down internal walls and foster relationships around an ecosystem of innovation,” says Dan Nguyen, Responsible for Innovation and Entrepreneurship at ISAE-SUPAERO.
The prototyping area on the ground floor offers equipment dedicated to mechanics, electronics and 3D printing. Two Fab Managers are on hand to provide technical advice and oversee all activities. The Digital Lab zone offers a free-access video studio, a virtual and augmented reality space as well as a concurrent engineering centre. The ground floor also houses an events space, a showroom and a small meeting room.
From idea to reality
The first floor of the InnovSpace is dedicated to start-ups and student projects and can welcome up to 30 people. Four start-ups are already set up : Dron’Aero develops drones for agriculture, Hinfact works on a neuroergonomics concept, Beyond Aerospace works on building a launcher for nanosatellites and alumni Amaury Ciurana, 2020 graduate, who works on a therapeutic exoskeleton.
As for student projects, InnovSpace will welcome I-CARE, a robotic arm that detects spatial waste, Solarboost, a mobile tricycle with an electric engine powered by solar panels, Green House on Mars, an automated hydroponic greenhouse to feed future martian settlers and finally Diamant BP4, an alumni project reproducing the historic French rocket. A team of teacher researchers is here to help students with their projects.
InnovSpace is supported by the ISAE-SUPAERO Foundation
To finance the build and equipment, the ISAE-SUPAERO Foundation has been fundraising for over a year. A total of 216 000 euros have been collected.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005688/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom